EMERYVILLE, Calif., Feb. 23 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported its financial results for the full year and fourth quarter 2009. Global Nexavar net sales as recorded by Onyx’s collaborator, Bayer HealthCare Pharmaceuticals, Inc., or Bayer, were $843.5 million for the full year 2009 and $235.2 million for the fourth quarter 2009 compared to $677.8 million and $176.5 million for the same periods in 2008. Onyx and Bayer are marketing and developing Nexavar® (sorafenib) tablets, an anticancer therapy currently approved for the treatment of liver cancer and advanced kidney cancer in the U.S., European Union, Japan and other territories.
